Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice
Fig 5
Anti-env Ab response is protective against subcutaneous B16F10 challenge.
(A) Naive mice were inoculated with 105 B16F10 cells on day 0 and treated with 200 μg TA99 (n = 5), 1E4.2.1 (n = 5), or PBS (n = 5) on days -1, 2, 5, 8, 11. Arrows indicate treatment points. Shown are tumor area curves and overall survival. (B) Age-matched mice (n = 5) and naive mice vaccinated five times with 10 μg RBD and 5 μg saponin-MPLA nanoparticles (n = 5) were challenged with 105 B16F10 cells. Shown are tumor area curves and overall survival. *P < 0.05 and **P < 0.01.